Compare Amgen, Inc. (AMGN) vs KraneShares CSI China Internet ETF (KWEB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs KraneShares CSI China Internet ETF — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while KraneShares CSI China Internet ETF trades at $26.27. The key difference: Amgen, Inc. pays a 2.77% dividend while KraneShares CSI China Internet ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | KWEB | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Sector/Thematic |
52-Week High | $388.16 | $42.94 |
52-Week Low | $271.18 | $23.63 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
KWEB trades at $26.38, down 0.38% on the day, with technical indicators showing mixed signals - bullish moving averages but neutral oscillators. The ETF offers concentrated exposure to Chinese internet and AI companies, currently trading near 52-week lows according to Seeking Alpha analysis from June 29, 2026. Recent news highlights China's significant AI infrastructure investments and strong export performance, providing potential catalysts for the underlying holdings.
The ETF presents a value opportunity with Chinese tech stocks trading at discounts to Western peers, though geopolitical tensions and regulatory risks remain concerns. AI-driven growth and government support for technology sectors offer upside potential, but investors face China-specific market volatility and US-China trade friction risks that could impact performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →
